We thank dr. Miao and coll． [1] for their interest in our review, Renal protection in heart failure with reduced ejection fraction: not all that glitters is gold [2], and for their comments on the clinical implementation of guideline-directed medical therapy (GDMT) in patients with concomitant chronic kidney disease (CKD). We are pleased that the main messages of our work—particularly the central role of sodium–glucose cotransporter-2 inhibitors (SGLT2i) in contemporary cardiorenal management—were clearly recognized.
